ADAPTIVE BIOTECHNOLOGIES CORPORATION Net Income
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Net Income of -$39.79 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$39.79M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$20.03M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$13.58M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net income (loss) attributable to parent for the quarter ending 2025-09-30 was $9.55M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net income (loss) attributable to parent for fiscal 2025 was -$59.50M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net income (loss) attributable to parent for fiscal 2024 was -$159.49M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net income (loss) attributable to parent for fiscal 2023 was -$225.25M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net income (loss) attributable to parent for fiscal 2022 was -$200.19M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$39.79M 10-Q · filed 2026-08-04 | -$59.82M 10-Q · filed 2026-08-04 | -$73.40M derived: sum of 3 quarters · filed 2026-08-04 | -$63.85M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$20.03M 10-Q · filed 2026-05-05 | -$33.61M derived: sum of 2 quarters · filed 2026-05-05 | -$24.07M derived: sum of 3 quarters · filed 2026-05-05 | -$49.68M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$13.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$4.03M derived: sum of 2 quarters · filed 2026-02-26 | -$29.65M derived: sum of 3 quarters · filed 2026-08-04 | -$59.50M 10-K · filed 2026-02-26 |
| 2025-09-30 | $9.55M 10-Q · filed 2025-11-05 | -$16.07M derived: sum of 2 quarters · filed 2026-08-04 | -$45.92M 10-Q · filed 2025-11-05 | -$79.61M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$25.61M 10-Q · filed 2026-08-04 | -$55.47M 10-Q · filed 2026-08-04 | -$89.16M derived: sum of 3 quarters · filed 2026-08-04 | -$121.23M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$29.85M 10-Q · filed 2026-05-05 | -$63.54M derived: sum of 2 quarters · filed 2026-05-05 | -$95.61M derived: sum of 3 quarters · filed 2026-05-05 | -$141.84M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$33.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$65.76M derived: sum of 2 quarters · filed 2026-02-26 | -$111.98M derived: sum of 3 quarters · filed 2026-02-26 | -$159.49M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$32.07M 10-Q · filed 2025-11-05 | -$78.29M derived: sum of 2 quarters · filed 2025-11-05 | -$125.80M 10-Q · filed 2025-11-05 | -$195.24M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$46.22M 10-Q · filed 2025-08-05 | -$93.73M 10-Q · filed 2025-08-05 | -$163.17M derived: sum of 3 quarters · filed 2026-02-26 | -$213.47M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$47.51M 10-Q · filed 2025-05-01 | -$116.95M derived: sum of 2 quarters · filed 2026-02-26 | -$167.25M derived: sum of 3 quarters · filed 2026-02-26 | -$215.06M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$69.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$119.74M derived: sum of 2 quarters · filed 2026-02-26 | -$167.55M derived: sum of 3 quarters · filed 2026-02-26 | -$225.25M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$50.30M 10-Q · filed 2024-11-07 | -$98.11M derived: sum of 2 quarters · filed 2024-11-07 | -$155.81M 10-Q · filed 2024-11-07 | -$195.94M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$47.81M 10-Q · filed 2024-08-01 | -$105.51M 10-Q · filed 2024-08-01 | -$145.64M derived: sum of 3 quarters · filed 2025-03-03 | -$190.92M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$57.70M 10-Q · filed 2024-05-07 | -$97.83M derived: sum of 2 quarters · filed 2025-03-03 | -$143.11M derived: sum of 3 quarters · filed 2025-03-03 | -$195.15M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$40.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$85.41M derived: sum of 2 quarters · filed 2025-03-03 | -$137.46M derived: sum of 3 quarters · filed 2025-03-03 | -$200.19M 10-K · filed 2025-03-03 |
| 2022-09-30 | -$45.28M 10-Q · filed 2023-11-09 | -$97.33M derived: sum of 2 quarters · filed 2023-11-09 | -$160.06M 10-Q · filed 2023-11-09 | -$221.50M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$52.05M 10-Q · filed 2023-08-02 | -$114.78M 10-Q · filed 2023-08-02 | -$176.22M derived: sum of 3 quarters · filed 2024-02-29 | -$232.12M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$62.74M 10-Q · filed 2023-05-03 | -$124.17M derived: sum of 2 quarters · filed 2024-02-29 | -$180.07M derived: sum of 3 quarters · filed 2024-02-29 | -$229.37M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$61.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$117.34M derived: sum of 2 quarters · filed 2024-02-29 | -$166.64M derived: sum of 3 quarters · filed 2024-02-29 | -$207.28M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$55.90M 10-Q · filed 2022-11-03 | -$105.20M derived: sum of 2 quarters · filed 2022-11-03 | -$145.85M 10-Q · filed 2022-11-03 | -$190.42M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | -$49.30M 10-Q · filed 2022-08-03 | -$89.94M 10-Q · filed 2022-08-03 | -$134.51M derived: sum of 3 quarters · filed 2023-02-14 | -$171.23M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | -$40.64M 10-Q · filed 2022-05-04 | -$85.21M derived: sum of 2 quarters · filed 2023-02-14 | -$121.93M derived: sum of 3 quarters · filed 2023-02-14 | -$155.47M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | -$44.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | -$81.29M derived: sum of 2 quarters · filed 2023-02-14 | -$114.82M derived: sum of 3 quarters · filed 2023-02-14 | -$146.23M 10-K · filed 2023-02-14 |
| 2020-09-30 | -$36.72M 10-Q · filed 2021-11-03 | -$70.25M derived: sum of 2 quarters · filed 2021-11-03 | -$101.66M 10-Q · filed 2021-11-03 | -$122.27M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | -$33.53M 10-Q · filed 2021-08-04 | -$64.94M 10-Q · filed 2021-08-04 | -$85.55M derived: sum of 3 quarters · filed 2022-02-15 | -$99.50M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | -$31.40M 10-Q · filed 2021-05-05 | -$52.01M derived: sum of 2 quarters · filed 2022-02-15 | -$65.96M derived: sum of 3 quarters · filed 2022-02-15 | -$81.62M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | -$20.61M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | -$34.56M derived: sum of 2 quarters · filed 2022-02-15 | -$50.22M derived: sum of 3 quarters · filed 2022-02-15 | -$68.61M 10-K · filed 2022-02-15 |
| 2019-09-30 | -$13.95M 10-Q · filed 2020-11-10 | -$29.61M derived: sum of 2 quarters · filed 2020-11-10 | -$47.99M 10-Q · filed 2020-11-10 | -$61.27M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | -$15.66M 10-Q · filed 2020-08-10 | -$34.05M 10-Q · filed 2020-08-10 | -$47.32M derived: sum of 3 quarters · filed 2021-02-24 | -$55.61M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | -$18.39M 10-Q · filed 2020-05-12 | -$31.66M derived: sum of 2 quarters · filed 2021-02-24 | -$39.95M derived: sum of 3 quarters · filed 2021-02-24 | -$52.44M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | -$13.27M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | -$21.56M derived: sum of 2 quarters · filed 2021-02-24 | -$34.06M derived: sum of 3 quarters · filed 2021-02-24 | -$46.45M 10-K · filed 2021-02-24 |
| 2018-09-30 | -$8.29M 10-Q · filed 2019-11-12 | -$20.79M derived: sum of 2 quarters · filed 2019-11-12 | -$33.18M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | -$12.49M 10-Q · filed 2019-08-13 | -$24.88M 10-Q · filed 2019-08-13 | ||
| 2017-12-31 | -$42.83M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |